Case number 2018-1397
UCB, Inc. v. Watson Laboratories Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | UCB, INC. v. WATSON LABORATORIES INC. [OPINION - PRECEDENTIAL] [precedential] (0) |
| Jul 31, 2019 | 80 | Mandate issued to the United States District Court for the District of Delaware. Service as of this date by the Clerk of Court. [624768] [18-1397, 18-1453] [JAB] [Entered: 07/31/2019 10:22 AM] (1) |
| Jun 24, 2019 | 79 | JUDGMENT filed. AFFIRMED. Terminated on the merits after oral argument. COSTS: No Costs. Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [616261] [18-1397, 18-1453] [JAB] [Entered: 06/24/2019 09:47 AM] (2) |
| Jun 24, 2019 | 78 | OPINION filed for the court by Taranto, Circuit Judge; Schall, Circuit Judge and Chen, Circuit Judge. Precedential Opinion. [616260] [18-1397, 18-1453] [JAB] [Entered: 06/24/2019 09:46 AM] (34) |
| Apr 3, 2019 | 77 | Submitted after ORAL ARGUMENT by John C. O'Quinn for Watson Laboratories Inc. and Actavis Laboratories UT, Inc. and Jack B. Blumenfeld for UCB, Inc., LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbH and UCB Manufacturing Ireland Limited. Panel: Judge: Taranto , Judge: Schall , Judge: Chen. [597486] [JAB] [Entered: 04/03/2019 10:51 AM] (0) |
| Mar 15, 2019 | 76 | Response to notice of oral argument from the Cross-Appellants LTS Lohmann Therapie-Systeme AG, UCB Manufacturing Ireland Limited, UCB Pharma GmbH and UCB, Inc.. [593254] [18-1397] [Jack Blumenfeld] [Entered: 03/15/2019 03:31 PM] (3) |
| Mar 15, 2019 | 75 | Response to notice of oral argument from the Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. [593249] [18-1397] [William Burgess] [Entered: 03/15/2019 03:15 PM] (3) |
| Feb 22, 2019 | 74 | NOTICE OF ORAL ARGUMENT. Panel: 1904J. Case scheduled Apr 03, 2019 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 201. Response to Notice of Oral Argument due: 03/15/2019. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. [588070] [JAB] [Entered: 02/22/2019 03:08 PM] (2) |
| Feb 4, 2019 | 73 | Notice from Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc. regarding conflicts with oral argument. Service: 02/04/2019 by email. [583032] [18-1397] [John O'Quinn] [Entered: 02/04/2019 10:16 AM] (2) |
| Dec 11, 2018 | 72 | Notice from Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc. regarding conflicts with oral argument. Service: 12/11/2018 by email. [570968] [18-1397] [John O'Quinn] [Entered: 12/11/2018 03:22 PM] (2) |
| Oct 30, 2018 | 71 | Notice from Cross-Appellants UCB, Inc., UCB Manufacturing Ireland Limited, UCB Pharma GmbH and LTS Lohmann Therapie-Systeme AG regarding conflicts with oral argument. Service: 10/30/2018 by email. [561482] [18-1397] [James Trainor] [Entered: 10/30/2018 05:37 PM] (2) |
| Oct 30, 2018 | 70 | Notice from Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc. regarding conflicts with oral argument. Service: 10/30/2018 by email. [561451] [18-1397] [Calvin Shank] [Entered: 10/30/2018 04:34 PM] (2) |
| Oct 29, 2018 | 69 | 6 paper copies of the Confidential Joint Appendix Brief (Vol. I - III) [64] received from Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. [561220] [CJF] [Entered: 10/30/2018 11:02 AM] (0) |
| Oct 23, 2018 | 68 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellants Actavis Laboratories UT, Inc., Watson Laboratories Inc. and Cross-Appellants LTS Lohmann Therapie-Systeme AG, UCB Manufacturing Ireland Limited, UCB Pharma GmbH and UCB, Inc.. Service: 10/23/2018 by email. [559794] [18-1397] [William Burgess] [Entered: 10/23/2018 07:24 PM] (3) |
| Oct 23, 2018 | 67 | Joint Statement of Compliance with Fed. Cir. R. 33 for Appellants Actavis Laboratories UT, Inc., Watson Laboratories Inc. and Cross-Appellants LTS Lohmann Therapie-Systeme AG, UCB Manufacturing Ireland Limited, UCB Pharma GmbH and UCB, Inc.. Service: 10/23/2018 by email. [559793] [18-1397] [William Burgess] [Entered: 10/23/2018 07:22 PM] (3) |
| Oct 23, 2018 | 66 | Notice to Advise of Scheduling Conflicts. Please advise of any scheduling conflicts during the upcoming court session months listed in the attached Notice. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [559447] [SJ] [Entered: 10/23/2018 10:57 AM] (1) |
| Oct 18, 2018 | 63 | 6 paper copies of the Reply Brief [60] received from Cross-Appellants LTS Lohmann Therapie-Systeme AG, UCB Manufacturing Ireland Limited, UCB Pharma GmbH and UCB, Inc.. [558507] [CJF] [Entered: 10/18/2018 02:18 PM] (0) |
| Oct 17, 2018 | 65 | APPENDIX FILED (3 vols.) for Actavis Laboratories UT, Inc. and Watson Laboratories Inc. [62]. Number of Pages: 1625. Service: 10/17/2018 by email. [559443] [SJ] [Entered: 10/23/2018 10:53 AM] (1631) |
| Oct 17, 2018 | 64 | CONFIDENTIAL JOINT APPENDIX FILED (3 vols.) for Actavis Laboratories UT, Inc. and Watson Laboratories Inc. [61]. Number of Pages: 1641. Service: 10/17/2018 by email. The paper copies of the brief should be received by the court on or before 10/30/2018. [559437] [SJ] [Entered: 10/23/2018 10:47 AM] (0) |
| Oct 17, 2018 | 62 | TENDERED from Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. Title: JOINT APPENDIX. Service: 10/17/2018 by email. [558299] [18-1397] [Calvin Shank] [Entered: 10/17/2018 08:42 PM] (1631) |
| Oct 17, 2018 | 61 | TENDERED from Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. Title: CONFIDENTIAL JOINT APPENDIX Service: 10/17/2018 by email. [558298] [18-1397] [Calvin Shank] [Entered: 10/17/2018 08:35 PM] (0) |
| Oct 11, 2018 | 59 | Notice from Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc. regarding conflicts with oral argument (request not to schedule oral argument during the same week as Nos. 17-1240 & 18-1054 (companion cases) or 17-2354, 18-1053, or 18-1376). Service: 10/11/2018 by email. [556539] [18-1397] [John O'Quinn] [Entered: 10/11/2018 10:12 PM] (2) |
| Oct 10, 2018 | 60 | REPLY BRIEF FILED for Cross-Appellants LTS Lohmann Therapie-Systeme AG, UCB Manufacturing Ireland Limited, UCB Pharma GmbH and UCB, Inc. [58]. Number of Pages: 25. Service: 10/10/2018 by email. The paper copies of the brief should be received by the court on or before 10/23/2018. Appendix is due 10/17/2018. [557660] [SJ] [Entered: 10/16/2018 02:37 PM] (34) |
| Oct 10, 2018 | 58 | TENDERED from Cross-Appellants LTS Lohmann Therapie-Systeme AG, UCB Manufacturing Ireland Limited, UCB Pharma GmbH and UCB, Inc.. Title: REPLY BRIEF. Service: 10/10/2018 by email. [556155] [18-1397] [James Trainor] [Entered: 10/10/2018 04:23 PM] (34) |
| Oct 9, 2018 | 57 | Amended Entry of appearance for Silvia M. Medina as of counsel for Cross-Appellants LTS Lohmann Therapie-Systeme AG, UCB Manufacturing Ireland Limited, UCB Pharma GmbH and UCB, Inc.. Service: 10/09/2018 by email. [555692] [18-1397] [James Trainor] [Entered: 10/09/2018 03:35 PM] (2) |
| Oct 9, 2018 | 56 | Amended Entry of appearance for Robert E. Counihan as of counsel for Cross-Appellants LTS Lohmann Therapie-Systeme AG, UCB Manufacturing Ireland Limited, UCB Pharma GmbH and UCB, Inc.. Service: 10/09/2018 by email. [555688] [18-1397] [James Trainor] [Entered: 10/09/2018 03:33 PM] (2) |
| Oct 9, 2018 | 55 | Amended Entry of appearance for Kevin X. McGann as of counsel for Cross-Appellants LTS Lohmann Therapie-Systeme AG, UCB Manufacturing Ireland Limited, UCB Pharma GmbH and UCB, Inc.. Service: 10/09/2018 by email. [555686] [18-1397] [James Trainor] [Entered: 10/09/2018 03:31 PM] (2) |
| Oct 9, 2018 | 54 | Amended Entry of appearance for Adam R. Gahtan as of counsel for Cross-Appellants LTS Lohmann Therapie-Systeme AG, UCB Manufacturing Ireland Limited, UCB Pharma GmbH and UCB, Inc.. Service: 10/09/2018 by email. [555684] [18-1397] [James Trainor] [Entered: 10/09/2018 03:28 PM] (2) |
| Oct 9, 2018 | 53 | Amended Entry of appearance for James S. Trainor, Jr. as principal counsel for Cross-Appellants LTS Lohmann Therapie-Systeme AG, UCB Manufacturing Ireland Limited, UCB Pharma GmbH and UCB, Inc.. Service: 10/09/2018 by email. [555681] [18-1397] [James Trainor] [Entered: 10/09/2018 03:25 PM] (2) |
| Oct 3, 2018 | 52 | **TEXT ONLY** ORDER granting motion to withdraw attorney [49] Eleanor Tennyson filed by Cross-Appellants UCB, Inc., LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbH and UCB Manufacturing Ireland Limited. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [554457] [SJ] [Entered: 10/03/2018 11:04 AM] (0) |
| Oct 3, 2018 | 51 | 6 paper copies of the Corrected Opening Brief [45] received from Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. [554432] [CJF] [Entered: 10/03/2018 10:40 AM] (0) |
| Oct 3, 2018 | 50 | 6 paper copies of the Corrected Response and Reply Brief [48] received from Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. [554413] [CJF] [Entered: 10/03/2018 10:23 AM] (0) |
| Sep 28, 2018 | 49 | MOTION of Cross-Appellants LTS Lohmann Therapie-Systeme AG, UCB Manufacturing Ireland Limited, UCB Pharma GmbH and UCB, Inc. to withdraw counsel Eleanor G. Tennyson [Consent: unopposed]. Service: 09/28/2018 by email. [553441] [18-1397] [Eleanor Tennyson] [Entered: 09/28/2018 06:31 PM] (7) |
| Sep 27, 2018 | 47 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: Cross-Appellants' motions [26] and [44] did not include certificates of compliance. CORRECTION: Pursuant to FRAP 32(g)(1), motions must contain a certificate of compliance with the word count. Please ensure future motions include the certificate of compliance. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [553087] [MJL] [Entered: 09/27/2018 04:10 PM] (0) |
| Sep 27, 2018 | 46 | **TEXT ONLY** ORDER granting motion to extend time to file brief [44] filed by Cross-Appellants UCB, Inc., LTS Lohmann Therapie-Systeme AG, et al. The brief is due 10/10/2018. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [553086] [MJL] [Entered: 09/27/2018 04:08 PM] (0) |
| Sep 24, 2018 | 44 | MOTION of Cross-Appellants UCB, Inc., UCB Pharma GmbH, UCB Manufacturing Ireland Limited and LTS Lohmann Therapie-Systeme AG to extend the time to 10/10/2018 to file the Reply Brief. [Consent: unopposed]. Service: 09/24/2018 by email. [552204] [18-1397] [James Trainor] [Entered: 09/24/2018 07:32 PM] (7) |
| Sep 20, 2018 | 43 | Notice of Correction to the Brief Doc No. [39] for Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. Service: 09/20/2018 by email. [551431] [18-1397] [William Burgess] [Entered: 09/20/2018 02:58 PM] (4) |
| Sep 19, 2018 | 41 | Notice of Correction to the Opening Brief Doc No. [24], Brief Doc No. [23] for Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. Service: 09/19/2018 by email. [551191] [18-1397] [William Burgess] [Entered: 09/19/2018 08:27 PM] (3) |
| Sep 19, 2018 | 39 | TENDERED from Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. Title: REPLY BRIEF. Service: 09/19/2018 by email. [551189] [18-1397]. This brief has been corrected. See Doc. No. [48]. [William Burgess] [Entered: 09/19/2018 08:24 PM] (0) |
| Sep 19, 2018 | 40 | TENDERED from Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. Title: CORRECTED OPENING BRIEF. Service: 09/19/2018 by email. [551190] [18-1397] [William Burgess] [Entered: 09/19/2018 08:25 PM] (203) |
| Sep 19, 2018 | 42 | TENDERED from Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. Title: REPLY BRIEF. Service: 09/19/2018 by email. [551198] [18-1397] [William Burgess] [Entered: 09/19/2018 11:18 PM] (83) |
| Sep 19, 2018 | 45 | CORRECTED BRIEF FILED for Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc. [40]. Number of Pages: 76. Service: 09/19/2018 by email. The paper copies of the brief should be received by the court on or before 10/04/2018. [553085] [MJL] [Entered: 09/27/2018 04:04 PM] (203) |
| Sep 19, 2018 | 48 | CORRECTED REPLY BRIEF FILED for Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc. [42]. Number of Pages: 71. Service: 09/19/2018 by email. The paper copies of the brief should be received by the court on or before 10/04/2018. [553095] [MJL] [Entered: 09/27/2018 04:24 PM] (83) |
| Aug 16, 2018 | 38 | 6 paper copies of the Opening Response Brief [37] received from Cross-Appellants LTS Lohmann Therapie-Systeme AG, UCB Manufacturing Ireland Limited, UCB Pharma GmbH and UCB, Inc.. [543402] [CJF] [Entered: 08/16/2018 12:58 PM] (0) |
| Aug 10, 2018 | 37 | BRIEF FILED for Cross-Appellants LTS Lohmann Therapie-Systeme AG, UCB Manufacturing Ireland Limited, UCB Pharma GmbH and UCB, Inc. [36]. Number of Pages: 71. Service: 08/10/2018 by email. The paper copies of the brief should be received by the court on or before 08/21/2018. Appellant's reply brief is due 09/19/2018. [542733] [SJ] [Entered: 08/14/2018 01:00 PM] (86) |
| Aug 10, 2018 | 36 | TENDERED from Cross-Appellants UCB, Inc., UCB Manufacturing Ireland Limited, UCB Pharma GmbH and LTS Lohmann Therapie-Systeme AG. Title: RESPONSE BRIEF. Service: 08/10/2018 by email. [542108] [18-1397] [James Trainor] [Entered: 08/10/2018 02:03 PM] (86) |
| Aug 9, 2018 | 35 | Entry of appearance for Silvia M. Medina as of counsel for Cross-Appellants UCB, Inc., UCB Manufacturing Ireland Limited, UCB Pharma GmbH and LTS Lohmann Therapie-Systeme AG. Service: 08/09/2018 by email. [541826] [18-1397] [Silvia Medina] [Entered: 08/09/2018 03:20 PM] (2) |
| Aug 9, 2018 | 34 | Entry of appearance for Eleanor G. Tennyson as of counsel for Cross-Appellants LTS Lohmann Therapie-Systeme AG, UCB Manufacturing Ireland Limited, UCB Pharma GmbH and UCB, Inc.. Service: 08/09/2018 by email. [541796] [18-1397] [Eleanor Tennyson] [Entered: 08/09/2018 02:10 PM] (2) |
| Aug 1, 2018 | 33 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:attorney entry of appearance Docket No. [31], ERROR: attorney's address reflects affiliation change but email on record does not match. CORRECTION: attorney should update ECF filing credentials to complete affiliation change from White & Case to Fenwick & West. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [540064] [SJ] [Entered: 08/01/2018 11:30 AM] (0) |
| Jul 31, 2018 | 32 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:attorney entry of appearance Docket No. [28], ERROR: attorney's email reflects affiliation change but address does not match. CORRECTION: attorney should update ECF filing credentials to complete affiliation change from White & Case to Fenwick & West. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [539863] [SJ] [Entered: 07/31/2018 04:14 PM] (0) |
| Jul 31, 2018 | 31 | Amended Entry of appearance for Robert Counihan as of counsel for Cross-Appellants UCB, Inc., UCB Pharma GmbH, UCB Manufacturing Ireland Limited and LTS Lohmann Therapie-Systeme AG. Service: 07/31/2018 by email. [539862] [18-1397] [Robert Counihan] [Entered: 07/31/2018 04:13 PM] (2) |
| Jul 31, 2018 | 30 | Amended Entry of appearance for Kevin McGann as of counsel for Cross-Appellants UCB, Inc., UCB Pharma GmbH, UCB Manufacturing Ireland Limited and LTS Lohmann Therapie-Systeme AG. Service: 07/31/2018 by email. [539798] [18-1397] [Kevin McGann] [Entered: 07/31/2018 03:04 PM] (2) |
| Jul 31, 2018 | 29 | Amended Entry of appearance for Adam Gahtan as of counsel for Cross-Appellants UCB, Inc., UCB Pharma GmbH, UCB Manufacturing Ireland Limited and LTS Lohmann Therapie-Systeme AG. Service: 07/31/2018 by email. [539795] [18-1397] [Adam Gahtan] [Entered: 07/31/2018 03:02 PM] (2) |
| Jul 31, 2018 | 28 | Amended Entry of appearance for James Trainor as principal counsel for Cross-Appellants UCB, Inc., UCB Manufacturing Ireland Limited, UCB Pharma GmbH and LTS Lohmann Therapie-Systeme AG. Service: 07/31/2018 by email. [539791] [18-1397] [James Trainor] [Entered: 07/31/2018 02:55 PM] (2) |
| May 9, 2018 | 27 | **TEXT ONLY** ORDER granting motion to extend time to file brief [26] filed by Cross-Appellants UCB, Inc., LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbH and UCB Manufacturing Ireland Limited. Brief due 08/10/2018. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [520449] [SJ] [Entered: 05/09/2018 03:22 PM] (0) |
| May 9, 2018 | 26 | MOTION of Cross-Appellants LTS Lohmann Therapie-Systeme AG, UCB Manufacturing Ireland Limited, UCB Pharma GmbH and UCB, Inc. to extend the time to 08/10/2018 to file the Principal Brief. [Consent: unopposed]. Service: 05/09/2018 by email. [520265] [18-1397] [Maryellen Noreika] [Entered: 05/09/2018 10:23 AM] (9) |
| May 8, 2018 | 25 | 6 paper copies of the Opening Brief [24] received from Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc. [520197] [JCP] [Entered: 05/09/2018 07:04 AM] (0) |
| May 2, 2018 | 24 | BRIEF FILED for Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc. [23]. Number of Pages: 76. Service: 05/02/2018 by email. The paper copies of the brief should be received by the court on or before 05/10/2018. Cross-Appellants LTS Lohmann Therapie-Systeme AG, UCB Manufacturing Ireland Limited, UCB Pharma GmbH and UCB, Inc. brief is due 06/11/2018. [518778]. This brief has been corrected. See Doc. No. [45]. [SJ] [Entered: 05/03/2018 12:47 PM] (0) |
| May 2, 2018 | 23 | TENDERED from Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. Title: OPENING BRIEF. Service: 05/02/2018 by email. [518654] [18-1397]. This brief has been corrected. See Doc. No. [45]. [William Burgess] [Entered: 05/02/2018 09:50 PM] (0) |
| Feb 15, 2018 | 22 | **TEXT ONLY** ORDER granting motion to extend time to file appellants' principal brief [21] filed by Appellants Watson Laboratories Inc. and Actavis Laboratories UT, Inc. Brief due 05/11/2018. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [497926] [SJ] [Entered: 02/15/2018 08:42 AM] (0) |
| Feb 14, 2018 | 21 | MOTION of Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc. to extend the time to 05/11/2018 to file the appellant/petitioner's principal brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 02/14/2018 by email. [497657] [William Burgess] [Entered: 02/14/2018 01:27 PM] (7) |
| Feb 2, 2018 | 20 | Entry of appearance for Derek J. Fahnestock as of counsel for Cross-Appellants LTS Lohmann Therapie-Systeme AG, UCB Manufacturing Ireland Limited, UCB Pharma GmbH and UCB, Inc.. Service: 02/02/2018 by email. [494896] [Jack Blumenfeld] [Entered: 02/02/2018 03:31 PM] (2) |
| Feb 2, 2018 | 19 | Entry of appearance for Maryellen Noreika as of counsel for Cross-Appellants LTS Lohmann Therapie-Systeme AG, UCB Manufacturing Ireland Limited, UCB Pharma GmbH and UCB, Inc.. Service: 02/02/2018 by email. [494893] [Jack Blumenfeld] [Entered: 02/02/2018 03:29 PM] (2) |
| Feb 2, 2018 | 18 | Entry of appearance for Jack B. Blumenfeld as of counsel for Cross-Appellants LTS Lohmann Therapie-Systeme AG, UCB Manufacturing Ireland Limited, UCB Pharma GmbH and UCB, Inc.. Service: 02/02/2018 by email. [494890] [Jack Blumenfeld] [Entered: 02/02/2018 03:27 PM] (2) |
| Feb 1, 2018 | 17 | Entry of appearance for Robert Counihan as of counsel for Cross-Appellants LTS Lohmann Therapie-Systeme AG, UCB Manufacturing Ireland Limited, UCB Pharma GmbH and UCB, Inc.. Service: 02/01/2018 by email. [494571] [Robert Counihan] [Entered: 02/01/2018 05:49 PM] (2) |
| Feb 1, 2018 | 16 | Entry of appearance for Kevin McGann as of counsel for Cross-Appellants LTS Lohmann Therapie-Systeme AG, UCB Manufacturing Ireland Limited, UCB Pharma GmbH and UCB, Inc.. Service: 02/01/2018 by email. [494570] [Kevin McGann] [Entered: 02/01/2018 05:43 PM] (2) |
| Feb 1, 2018 | 15 | Entry of appearance for Adam Gahtan as of counsel for Cross-Appellants LTS Lohmann Therapie-Systeme AG, UCB Manufacturing Ireland Limited, UCB Pharma GmbH and UCB, Inc.. Service: 02/01/2018 by email. [494569] [Adam Gahtan] [Entered: 02/01/2018 05:40 PM] (2) |
| Feb 1, 2018 | 14 | Docketing Statement for the Cross-Appellants LTS Lohmann Therapie-Systeme AG, UCB Manufacturing Ireland Limited, UCB Pharma GmbH and UCB, Inc.. Service: 02/01/2018 by email. [494563] [James Trainor] [Entered: 02/01/2018 05:34 PM] (3) |
| Feb 1, 2018 | 13 | Certificate of Interest for the Cross-Appellants LTS Lohmann Therapie-Systeme AG, UCB Manufacturing Ireland Limited, UCB Pharma GmbH and UCB, Inc.. Service: 02/01/2018 by email. [494560] [James Trainor] [Entered: 02/01/2018 05:32 PM] (5) |
| Feb 1, 2018 | 12 | Entry of appearance for James Trainor as principal counsel for Cross-Appellants LTS Lohmann Therapie-Systeme AG, UCB Manufacturing Ireland Limited, UCB Pharma GmbH and UCB, Inc.. Service: 02/01/2018 by email. [494559] [James Trainor] [Entered: 02/01/2018 05:29 PM] (2) |
| Jan 25, 2018 | 11 | Entry of appearance for C. Alex Shank as of counsel for Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. Service: 01/25/2018 by email. [492882] [William Burgess] [Entered: 01/25/2018 06:46 PM] (2) |
| Jan 25, 2018 | 10 | Entry of appearance for Christopher T. Jagoe as of counsel for Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. Service: 01/25/2018 by email. [492881] [William Burgess] [Entered: 01/25/2018 06:45 PM] (2) |
| Jan 25, 2018 | 9 | Entry of appearance for William H. Burgess as of counsel for Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. Service: 01/25/2018 by email. [492880] [William Burgess] [Entered: 01/25/2018 06:44 PM] (2) |
| Jan 25, 2018 | 8 | Entry of appearance for Thomas F. Fleming as of counsel for Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. Service: 01/25/2018 by email. [492879] [William Burgess] [Entered: 01/25/2018 06:43 PM] (2) |
| Jan 25, 2018 | 7 | Entry of appearance for Leora Ben-Ami as of counsel for Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. Service: 01/25/2018 by email. [492878] [William Burgess] [Entered: 01/25/2018 06:42 PM] (2) |
| Jan 25, 2018 | 6 | Entry of appearance for John C. O'Quinn as principal counsel for Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. Service: 01/25/2018 by email. [492877] [William Burgess] [Entered: 01/25/2018 06:41 PM] (2) |
| Jan 25, 2018 | 5 | Docketing Statement for the Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. Service: 01/25/2018 by email. [492876] [William Burgess] [Entered: 01/25/2018 06:40 PM] (3) |
| Jan 25, 2018 | 4 | Certificate of Interest for the Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. Service: 01/25/2018 by email. [492875] [William Burgess] [Entered: 01/25/2018 06:39 PM] (3) |
| Jan 23, 2018 | 3 | Official caption revised to reflect cross-appeal by plaintiffs. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by Clerk of Court. [491696] [SJ] [Entered: 01/23/2018 08:51 AM] (0) |
| Jan 23, 2018 | 2 | Note to file: The following cases are associated:18-1397 (lead) with 18-1453 (cross-appeal). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [491695] [18-1397, 18-1453] [SJ] [Entered: 01/23/2018 08:50 AM] (0) |
| Jan 11, 2018 | 1 | Appeal docketed. Received: 01/05/2018. [488920]Entry of Appearance due 01/25/2018. Certificate of Interest is due on 01/25/2018. Docketing Statement due 01/25/2018. Appellant/Petitioner's brief is due 03/12/2018. [SJ] [Entered: 01/11/2018 11:25 AM] (130) |
